You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF mutation-positive melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

Melanoma, Adjuvant Trial (Dabrafenib and Trametinib, Dabrafenib, Trametinib)

Available
  • Melanoma
  • Adjuvant
  • Dabrafenib and Trametinib
  • +2 more
  • (no location specified)
Mar 1, 2022

Dabrafenib in Combination With Trametinib as Adjuvant Treatment

Recruiting
  • Melanoma
  • Zhengzhou, Henan, China
  • +6 more
Mar 17, 2022

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

Completed
  • Metastatic Melanoma
  • Palliative radiotherapy
  • Dabrafenib and trametinib (combination)
  • Darlinghurst, New South Wales, Australia
  • +2 more
Apr 6, 2022

Cancer, Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Melanoma
  • Guangzhou, Guangdong, China
  • +12 more
Jan 4, 2022

Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

Recruiting
  • Melanoma
  • Siena, Toscana, Italy
  • +11 more
Jun 23, 2023

Malignant Melanoma, BRAF V600 Mutation, Brain Metastases Trial in France (Stereotaxic radiosurgery (SRS), Binimetinib Oral

Recruiting
  • Malignant Melanoma
  • +2 more
  • Stereotaxic radiosurgery (SRS)
  • +3 more
  • Bobigny, France
  • +20 more
Oct 7, 2022

Melanoma, Brain Metastases Trial in Canada (Dabrafenib, Trametinib)

Terminated
Has Results
  • Melanoma
  • Brain Metastases
  • Halifax, Nova Scotia, Canada
  • +5 more
Aug 18, 2021

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Baseline Metastases on Clinical Outcomes Among BRAF Positive

Completed
  • BRAF Positive Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis
    Aug 2, 2023

    Immunotherapy Among BRAF-Positive Melanoma Patients Treated in

    Completed
    • Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022

    Malignant Melanoma Trial in Germany (Dabrafenib, Trametinib)

    Terminated
    • Malignant Melanoma
    • Heidelberg, BW, Germany
    • +5 more
    Oct 13, 2020

    Melanoma Metastatic, BRAF V600 Mutation Trial in Italy (Experimental combination beyond Focal Progression, Pembrolizumab or

    Active, not recruiting
    • Melanoma Metastatic
    • BRAF V600 Mutation
    • Experimental combination beyond Focal Progression
    • Pembrolizumab or Nivolumab
    • Bari, BA, Italy
    • +13 more
    Dec 1, 2021

    Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

    Recruiting
    • Metastatic Melanoma
    • BRAF Gene Mutation
    • Nilotinib 100mg
    • +5 more
    • Lexington, Kentucky
      Markey Cancer Center
    Jul 22, 2022

    Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

    Not yet recruiting
    • Cancer
    • +5 more
    • (no location specified)
    Aug 18, 2022

    Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • BRAF V600E Mutation Positive
    • Encorafenib Oral Capsule + Cetuximab
    • (no location specified)
    Jan 30, 2023

    Melanoma, BRAF V600 Mutation, Unresectable Melanoma Trial in Rennes (Binimetinib Oral Tablet)

    Completed
    • Melanoma
    • +3 more
    • Binimetinib Oral Tablet
    • Rennes, France
      Biotrial
    Mar 31, 2023

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    Advanced Melanoma Trial in China (HLX208)

    Recruiting
    • Advanced Melanoma
    • Peking, Beijing, China
    • +6 more
    May 1, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

    Active, not recruiting
    • BRAF V600E Mutation Present
    • +9 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2022

    Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

    Recruiting
    • Melanoma (Skin)
    • +2 more
      • Evora, Portugal
        Hospital Evora
      May 30, 2022

      BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

      Terminated
      • BRAF V600E Mutation Present
      • +7 more
      • Boston, Massachusetts
      • +1 more
      Mar 9, 2022

      BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

      Completed
      Has Results
      • BRAF V600E Mutation
      • Dabrafenib Mesylate
      • Trametinib Dimethyl Sulfoxide
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Aug 6, 2021

      Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)

      Recruiting
      • Solid Tumor
      • +11 more
      • Belfast, United Kingdom
      • +16 more
      Mar 2, 2023